Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes

Familial hypercholesterolemia (FH) is an autosomal dominant condition that leads to significantly elevated low-density lipoprotein cholesterol (LDL-C) levels and an elevated risk for cardiovascular disease. Mipomersen is an antisense oligonucleotide inhibitor targeted to apolipoprotein B-100 (apoB-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Chambergo-Michilot, Diego, Alur, Anish, Kulkarni, Saneel, Agarwala, Anandita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880726/
https://www.ncbi.nlm.nih.gov/pubmed/35221690
http://dx.doi.org/10.2147/VHRM.S191965
_version_ 1784659290810744832
author Chambergo-Michilot, Diego
Alur, Anish
Kulkarni, Saneel
Agarwala, Anandita
author_facet Chambergo-Michilot, Diego
Alur, Anish
Kulkarni, Saneel
Agarwala, Anandita
author_sort Chambergo-Michilot, Diego
collection PubMed
description Familial hypercholesterolemia (FH) is an autosomal dominant condition that leads to significantly elevated low-density lipoprotein cholesterol (LDL-C) levels and an elevated risk for cardiovascular disease. Mipomersen is an antisense oligonucleotide inhibitor targeted to apolipoprotein B-100 (apoB-100) mRNA that is administered via subcutaneous injection. Once administered, mipomersen causes selective degradation of the apoB-100 mRNA and inhibition of protein translation. This ultimately results in substantial reductions in LDL-C and other lipoprotein levels. Mipomersen is approved for the treatment of homozygous FH. In this review, we discuss its mechanism, current evidence, limitations of use including adverse events, and impact on health-related quality of life.
format Online
Article
Text
id pubmed-8880726
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88807262022-02-26 Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes Chambergo-Michilot, Diego Alur, Anish Kulkarni, Saneel Agarwala, Anandita Vasc Health Risk Manag Review Familial hypercholesterolemia (FH) is an autosomal dominant condition that leads to significantly elevated low-density lipoprotein cholesterol (LDL-C) levels and an elevated risk for cardiovascular disease. Mipomersen is an antisense oligonucleotide inhibitor targeted to apolipoprotein B-100 (apoB-100) mRNA that is administered via subcutaneous injection. Once administered, mipomersen causes selective degradation of the apoB-100 mRNA and inhibition of protein translation. This ultimately results in substantial reductions in LDL-C and other lipoprotein levels. Mipomersen is approved for the treatment of homozygous FH. In this review, we discuss its mechanism, current evidence, limitations of use including adverse events, and impact on health-related quality of life. Dove 2022-02-21 /pmc/articles/PMC8880726/ /pubmed/35221690 http://dx.doi.org/10.2147/VHRM.S191965 Text en © 2022 Chambergo-Michilot et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Chambergo-Michilot, Diego
Alur, Anish
Kulkarni, Saneel
Agarwala, Anandita
Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes
title Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes
title_full Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes
title_fullStr Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes
title_full_unstemmed Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes
title_short Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes
title_sort mipomersen in familial hypercholesterolemia: an update on health-related quality of life and patient-reported outcomes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880726/
https://www.ncbi.nlm.nih.gov/pubmed/35221690
http://dx.doi.org/10.2147/VHRM.S191965
work_keys_str_mv AT chambergomichilotdiego mipomerseninfamilialhypercholesterolemiaanupdateonhealthrelatedqualityoflifeandpatientreportedoutcomes
AT aluranish mipomerseninfamilialhypercholesterolemiaanupdateonhealthrelatedqualityoflifeandpatientreportedoutcomes
AT kulkarnisaneel mipomerseninfamilialhypercholesterolemiaanupdateonhealthrelatedqualityoflifeandpatientreportedoutcomes
AT agarwalaanandita mipomerseninfamilialhypercholesterolemiaanupdateonhealthrelatedqualityoflifeandpatientreportedoutcomes

Ejemplares similares